Literature DB >> 29125780

Segmentation of Whole-Body Images into Two Compartments in Model for Bone Marrow Dosimetry Increases the Correlation with Hematological Response in 177Lu-DOTATATE Treatments.

Linn Hagmarker1, Johanna Svensson2, Tobias Rydén1, Peter Gjertsson3, Peter Bernhardt1.   

Abstract

BACKGROUND: In 177Lu-DOTATATE treatments, bone marrow (BM) is one of the most important organs at risk. The authors previously developed an image-based two-compartment method for BM dosimetry, showing a significant correlation between absorbed dose to BM and hematological toxicity in 177Lu-DOTATATE treatments. In the present study, they aimed to further evaluate this BM dosimetry method by finding optimal settings for dividing the whole body into two compartments; in terms of minimizing the coefficient of variation (CV) for the individual absorbed doses and studying its correlation to the BM response. The authors have also added specific absorbed fractions for male and female. Finally, they compare this two-compartment method with whole-body dosimetry.
METHODS: This study included 46 patients with advanced neuroendocrine tumors treated with 177Lu-DOTATATE on two to five occasions at Sahlgrenska University Hospital. Planar gamma camera images were collected at four time points postinjection, and a segmentation tool using a normalized number of uptake foci (nNUF) to divide the whole body into high- and low-uptake compartments was used. The authors characterized the two-compartment model and compared it with whole-body dosimetry. RESULTS AND
CONCLUSION: The dosimetry method was robust, with an optimal nNUF value of 0.1-0.2. Using an nNUF value of 0.15, the absorbed BM dose was estimated as 0.20 Gy/7.4 GBq, and the CV as 8.4%. Compared to whole-body dosimetry, stronger correlation was found between absorbed dose to BM and hematological response using the two-compartment method. The two-compartment method has potential as a valuable image-based alternative to blood-based BM dosimetry.

Entities:  

Keywords:  177Lu-DOTATATE; bone marrow dosimetry; hematological response

Mesh:

Substances:

Year:  2017        PMID: 29125780     DOI: 10.1089/cbr.2017.2317

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  3 in total

1.  Accuracy and reproducibility of simplified QSPECT dosimetry for personalized 177Lu-octreotate PRRT.

Authors:  Michela Del Prete; Frédéric Arsenault; Nassim Saighi; Wei Zhao; François-Alexandre Buteau; Anna Celler; Jean-Mathieu Beauregard
Journal:  EJNMMI Phys       Date:  2018-10-15

2.  Bone Marrow Absorbed Doses and Correlations with Hematologic Response During 177Lu-DOTATATE Treatments Are Influenced by Image-Based Dosimetry Method and Presence of Skeletal Metastases.

Authors:  Linn Hagmarker; Johanna Svensson; Tobias Rydén; Martijn van Essen; Anna Sundlöv; Katarina Sjögreen Gleisner; Peter Gjertsson; Peter Bernhardt
Journal:  J Nucl Med       Date:  2019-03-22       Impact factor: 10.057

3.  EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands.

Authors:  Katarina Sjögreen Gleisner; Nicolas Chouin; Pablo Minguez Gabina; Francesco Cicone; Silvano Gnesin; Caroline Stokke; Mark Konijnenberg; Marta Cremonesi; Frederik A Verburg; Peter Bernhardt; Uta Eberlein; Jonathan Gear
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-03-14       Impact factor: 10.057

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.